|
1
|
Toward improving Caenorhabditis elegans phenome mapping with an ORFeome-based RNAi library.
|
Genome Res
|
2004
|
5.81
|
|
2
|
Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation.
|
Blood
|
2007
|
2.57
|
|
3
|
Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation.
|
Blood
|
2007
|
2.54
|
|
4
|
Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease.
|
Blood
|
2009
|
2.50
|
|
5
|
Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning.
|
J Clin Oncol
|
2008
|
2.44
|
|
6
|
Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation.
|
Blood
|
2011
|
2.41
|
|
7
|
Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis.
|
Blood
|
2010
|
2.16
|
|
8
|
Immune reconstitution after double umbilical cord blood stem cell transplantation: comparison with unrelated peripheral blood stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2011
|
2.11
|
|
9
|
Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease.
|
Sci Transl Med
|
2013
|
2.03
|
|
10
|
Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation.
|
J Clin Invest
|
2010
|
2.00
|
|
11
|
A disease risk index for patients undergoing allogeneic stem cell transplantation.
|
Blood
|
2012
|
2.00
|
|
12
|
Clearance of CMV viremia and survival after double umbilical cord blood transplantation in adults depends on reconstitution of thymopoiesis.
|
Blood
|
2010
|
1.88
|
|
13
|
Prediction of veno-occlusive disease using biomarkers of endothelial injury.
|
Biol Blood Marrow Transplant
|
2010
|
1.76
|
|
14
|
Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation.
|
Blood
|
2013
|
1.72
|
|
15
|
Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation.
|
Blood
|
2008
|
1.71
|
|
16
|
Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome.
|
Biol Blood Marrow Transplant
|
2008
|
1.69
|
|
17
|
Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis.
|
Blood
|
2007
|
1.44
|
|
18
|
Costs of allogeneic hematopoietic cell transplantation with high-dose regimens.
|
Biol Blood Marrow Transplant
|
2008
|
1.41
|
|
19
|
Ibrutinib treatment ameliorates murine chronic graft-versus-host disease.
|
J Clin Invest
|
2014
|
1.38
|
|
20
|
Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation.
|
Proc Natl Acad Sci U S A
|
2009
|
1.34
|
|
21
|
Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells.
|
J Clin Invest
|
2013
|
1.30
|
|
22
|
Selection of optimal alternative graft source: mismatched unrelated donor, umbilical cord blood, or haploidentical transplant.
|
Blood
|
2011
|
1.27
|
|
23
|
Use of matched unrelated donors compared with matched related donors is associated with lower relapse and superior progression-free survival after reduced-intensity conditioning hematopoietic stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2010
|
1.22
|
|
24
|
Reduced-intensity conditioning stem cell transplantation: comparison of double umbilical cord blood and unrelated donor grafts.
|
Biol Blood Marrow Transplant
|
2011
|
1.19
|
|
25
|
Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial.
|
Blood
|
2013
|
1.14
|
|
26
|
Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2010
|
1.13
|
|
27
|
Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2009
|
1.10
|
|
28
|
Cord-blood hematopoietic stem cell transplant confers an increased risk for human herpesvirus-6-associated acute limbic encephalitis: a cohort analysis.
|
Biol Blood Marrow Transplant
|
2012
|
1.10
|
|
29
|
Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies.
|
Biol Blood Marrow Transplant
|
2013
|
1.08
|
|
30
|
High-resolution HLA matching in double-umbilical-cord-blood reduced-intensity transplantation in adults.
|
Transfusion
|
2009
|
1.06
|
|
31
|
Outcome and prognostic factors for patients who relapse after allogeneic hematopoietic stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2013
|
1.06
|
|
32
|
The impact of geographic proximity to transplant center on outcomes after allogeneic hematopoietic stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2011
|
1.06
|
|
33
|
A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2007
|
1.01
|
|
34
|
Does iron overload really matter in stem cell transplantation?
|
Am J Hematol
|
2012
|
0.99
|
|
35
|
Donor-derived second hematologic malignancies after cord blood transplantation.
|
Biol Blood Marrow Transplant
|
2010
|
0.98
|
|
36
|
Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
|
Biol Blood Marrow Transplant
|
2013
|
0.96
|
|
37
|
Seroprotective titers against 2009 H1N1 influenza A virus after vaccination in allogeneic hematopoietic stem cell transplantation recipients.
|
Biol Blood Marrow Transplant
|
2010
|
0.92
|
|
38
|
Iron overload in hematologic malignancies and outcome of allogeneic hematopoietic stem cell transplantation.
|
Haematologica
|
2010
|
0.92
|
|
39
|
Hyperlipidemia and statin use after allogeneic hematopoietic stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2011
|
0.90
|
|
40
|
Low telomerase activity in CD4+ regulatory T cells in patients with severe chronic GVHD after hematopoietic stem cell transplantation.
|
Blood
|
2011
|
0.88
|
|
41
|
Optimal positioning of hematopoietic stem cell transplantation for older patients with myelodysplastic syndromes.
|
Curr Opin Hematol
|
2013
|
0.87
|
|
42
|
Phase II trial of parathyroid hormone after double umbilical cord blood transplantation.
|
Biol Blood Marrow Transplant
|
2012
|
0.83
|
|
43
|
White blood cell recovery after allogeneic hematopoietic cell transplantation predicts clinical outcome.
|
Am J Hematol
|
2014
|
0.79
|
|
44
|
Novel strategies to prevent relapse after allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia and myelodysplastic syndromes.
|
Curr Opin Hematol
|
2015
|
0.79
|
|
45
|
Emerging therapies in hematopoietic stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2012
|
0.76
|
|
46
|
Phase I study of alemtuzumab for therapy of steroid-refractory chronic graft-versus-host disease.
|
Biol Blood Marrow Transplant
|
2013
|
0.75
|
|
47
|
Blood stem cell transplantation in older patients.
|
Biol Blood Marrow Transplant
|
2009
|
0.75
|